Biological approaches to generating cardiac biopacemaker for bradycardia.
- Author:
Yong-Fu XIAO
1
;
Daniel C SIGG
Author Information
1. Cardiac Rhythm Disease Management, Medtronic Inc., Minneapolis, MN 55432, USA. yong-fu.xiao@medtronic.com
- Publication Type:Journal Article
- MeSH:
Biological Clocks;
physiology;
Bradycardia;
therapy;
Genetic Engineering;
Heart;
Heart Rate;
Heart Ventricles;
Humans;
Ion Channels;
Myocardium;
Pacemaker, Artificial;
Sinoatrial Node
- From:
Acta Physiologica Sinica
2007;59(5):562-570
- CountryChina
- Language:English
-
Abstract:
Normal rhythm in a healthy human heart originates from the natural biological pacemaker, the sinoatrial (SA) node which locates in the right atrium. SA node dysfunction or atrial-ventricular (AV) conduction block causes improper heart rate (bradycardia). Such dysfunction, if severe enough, is currently treated by implanting an electronic pacemaker which has been well established technically, but there are some limitations and inadequacies. Recently, progress in developing engineered cardiac biopacemakers with use of genes or cells has been made in experimental animal models. The hyperpolarization-activated cyclic-nucleotide-modulated (HCN) channel (pacemaker channel) modulates cardiac automaticity via the hyperpolarization-activated cation current (I(f)). HCN genes have been delivered to animal myocardium via viral vectors or HCN-transferred cells for recreating biological pacemakers. Approaches with non-HCN genes or transplantation of beating cells are also novel and have been investigated for generating cardiac biopacers. This article summarizes the progresses in research on recreation of cardiac biopacemakers. Genetically engineered biological pacemaker holds great promise to potentially cure severe bradycardia if critical issues, such as their stability and longevity, are properly solved.
